Posted by Michael Wonder on 17 Sep 2024
Rucaparib camsylate for the maintenance treatment of patients with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (final guidance)
17 September 2024 - NICE has published final evidence-based recommendations on the use of rucaparib camsylate (Rubraca) for the maintenance treatment of adults with relapsed platinum-sensitive high grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy.
Rucaparib camsylate is recommended as an option for the maintenance treatment of adults with relapsed platinum-sensitive high grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy. Rucaparib camsylate is only recommended if pharma& provides it according to the commercial arrangement.
